Heron Therapeutics, Inc. (NASDAQ:HRTX) is a commercial-stage biotechnology company focused on developing treatments for pain management and cancer. The company operates in the competitive Zacks Medical - Drugs industry. Heron Therapeutics' key products include ZYNRELEF and APONVIE, which have shown significant revenue growth due to strategic initiatives and enhanced distribution programs.
On November 4, 2025, Heron Therapeutics reported its earnings before the market opened. The company posted an earnings per share (EPS) of -$0.10, which was below the estimated EPS of -$0.01. This marks a decline from the previous year's loss of $0.03 per share, resulting in a negative surprise of 150%.
Heron Therapeutics' revenue for the quarter was $38.21 million, falling short of the estimated $39.03 million. Despite this, the company achieved a 16.5% increase in revenue compared to the same period last year. However, the revenue figure fell short of the Zacks Consensus Estimate of $38.57 million, resulting in a revenue surprise of -0.91%. Over the last four quarters, Heron Therapeutics has surpassed consensus revenue estimates twice.
The company's financial metrics, such as a price-to-earnings (P/E) ratio of approximately -182.81 and a price-to-sales ratio of about 1.13, indicate negative earnings and suggest that investors are paying $1.13 for every dollar of the company's sales. The enterprise value to sales ratio is approximately 2.20, providing insight into the company's valuation relative to its sales. The debt-to-equity ratio is about -6.48, highlighting a significant level of debt relative to equity.
Heron Therapeutics remains optimistic about its future, reaffirming its 2025 net revenue guidance, projecting between $153 million and $163 million, with an adjusted EBITDA ranging from $9 million to $13 million. The company is focused on the impact of new initiatives launched in the third quarter, which are showing positive signs of enhancing their commercial performance.
